Messenger

Watchmaker Genomics Launches Watchmaker mRNA Library Prep Kits - Featuring a Rapid Workflow and Sensitive mRNA Detection

Retrieved on: 
Tuesday, March 26, 2024
Medical Supplies, Medical Devices, Health, Genetics, Other Health, Biotechnology, Watchmaker, Polaris, Genomics, RNA, DNA, Gene expression, Messenger, Small RNA, Vaccine

Watchmaker Genomics, a supplier of innovative products for molecular analysis, announced the launch of the Watchmaker mRNA Library Prep Kit – designed to streamline and accelerate mRNA library preparation, offering both speed and sensitivity to the genomics community.

Key Points: 
  • Watchmaker Genomics, a supplier of innovative products for molecular analysis, announced the launch of the Watchmaker mRNA Library Prep Kit – designed to streamline and accelerate mRNA library preparation, offering both speed and sensitivity to the genomics community.
  • The Watchmaker mRNA Library Prep Kit generates high-quality mRNA libraries in under 5 hours with fewer handling and purification steps.
  • Additionally, it delivers exceptionally sensitive and accurate gene expression data, enabling researchers to uncover valuable biological insights.
  • "We are thrilled to make this kit widely available," said Brian Kudlow, Chief Scientific Officer at Watchmaker.

Global Contract Development and Manufacturing Organization Market Analysis Report 2023-2024 and 2029: Flexible and Scalable Manufacturing Processes Shaping the CDMO Landscape - ResearchAndMarkets.com

Retrieved on: 
Friday, March 22, 2024
Chemicals, Plastics, Health, Manufacturing, Other Manufacturing, Pharmaceutical, Biotechnology, Catalent, CDMO, Growth, Prevalence, Cardiovascular disease, A-DNA, Application, COVID-19, Patient, Conditional sentence, Samsung Biologics, Research, Diabetes, Messenger, WuXi Biologics, Investment, Antibody, Drug development, Workforce, API, Glaucoma, Vaccine, CMOS, Fine chemical

The global contract development and manufacturing organization (CDMO) market was valued at US$124.38 billion in 2023, and is expected to be worth US$256.90 billion in 2029.

Key Points: 
  • The global contract development and manufacturing organization (CDMO) market was valued at US$124.38 billion in 2023, and is expected to be worth US$256.90 billion in 2029.
  • The "contract development manufacturing organization (CDMO)" model has emerged in response to growing demand.
  • CDMOs, third-party providers, specialize in developing and manufacturing production processes for pharmaceutical firms, offering support throughout the drug-making journey.
  • The growing importance of specialized services, spanning early-stage development to commercial manufacturing, underscores the expanding role of CDMOs in the entire drug development lifecycle.

Elegen Launches ENFINIA™ DNA Enhancement for Rapid Synthesis of Highly Complex DNA

Retrieved on: 
Wednesday, March 20, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, SV40, Associate, GSK, NGS, RNA, DNA, EAP, Messenger, Cauliflower mosaic virus, Doctor of Philosophy, Lentivirus, Therapy, IRES, Access, Orbital, IVT, Vaccine

This upgrade to ENFINIA DNA sets a new standard for DNA manufacturing, providing an industry-leading combination of speed, length, NGS-verified accuracy and complexity.

Key Points: 
  • This upgrade to ENFINIA DNA sets a new standard for DNA manufacturing, providing an industry-leading combination of speed, length, NGS-verified accuracy and complexity.
  • EAP partners received long and very complex DNA sequences that were either rejected by other suppliers or would have taken months to synthesize.
  • Elegen commercially launched ENFINIA DNA in Q1 2023 , delivering NGS-verified, linear DNA up to 7kb in 6 to 8 business days.
  • This latest enhancement of ENFINIA DNA to produce high-complexity DNA marks another step in the company’s mission to develop innovative solutions for DNA manufacturing, including even longer DNA, plasmid DNA and clinical-grade DNA production.

Merck Invests More than € 300 Million in New Life Science Production Site in Korea

Retrieved on: 
Wednesday, March 20, 2024
Chemicals, Plastics, Health, Manufacturing, Health Technology, Pharmaceutical, Biotechnology, Science, Public, Health care, Messenger, Multimedia, Vaccine, Pharmaceutical industry

Merck invests more than € 300 million into a new Bioprocessing Production Center in Daejeon, South Korea.

Key Points: 
  • Merck invests more than € 300 million into a new Bioprocessing Production Center in Daejeon, South Korea.
  • Merck expects the investment to create approximately 300 additional jobs by the end of 2028.
  • Established in 1989, Merck Korea has been consistently driving dynamic growth of the science and technology industries with more than 1,700 employees across Life Science, Healthcare and Electronics.
  • Merck Korea encompasses 13 sites in production and R&D including the M Lab™ Collaboration Center in Songdo, Incheon which serves biopharmaceutical companies in the region.

Capstan Therapeutics Announces $175M Oversubscribed Series B Financing

Retrieved on: 
Wednesday, March 20, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Polaris Partners, Cell, General partnership, Venture round, RNA, Messenger, Bristol Myers Squibb, MBA, Bayer, Therapy, OrbiMed, Immune system, Eli Lilly and Company, Series, Investment, Blood, Vaccine

Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced the successful closing of a $175M oversubscribed Series B financing.

Key Points: 
  • Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced the successful closing of a $175M oversubscribed Series B financing.
  • The Series B financing was led by RA Capital Management, with participation from new investors Forbion, Johnson & Johnson Innovation - JJDC, Mubadala Capital, Perceptive Advisors, and Sofinnova Investments.
  • The proceeds from the Series B financing will be used to advance CPTX2309, Capstan’s lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders, and to further develop Capstan’s tLNP pipeline.
  • “This Series B financing brings together an exceptional syndicate of investors that recognize the potential of Capstan’s in vivo CAR-T technology,” said Laura Shawver, Ph.D., President and Chief Executive Officer of Capstan.

MilliporeSigma Invests More than € 300 Million in New Life Science Production Site in Korea

Retrieved on: 
Wednesday, March 20, 2024
Research, Commercial Building & Real Estate, Construction & Property, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Other Science, Public, Health care, Merck, Messenger, Merck Group, Multimedia, Vaccine, Sigma-Aldrich, Pharmaceutical industry

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, invests more than €300 million into a new Bioprocessing Production Center in Daejeon, South Korea.

Key Points: 
  • MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, invests more than €300 million into a new Bioprocessing Production Center in Daejeon, South Korea.
  • The new site is the largest investment by the company’s Life Science business sector in Asia-Pacific to date and demonstrates its commitment to expanding its capacities in the fast-growing region.
  • The investment is expected to create approximately 300 additional jobs by the end of 2028.
  • Established in 1989, the Life Science business of Merck KGaA, Darmstadt, Germany in Korea has been consistently driving dynamic growth of the science and technology industries with more than 1,700 employees across Life Science, Healthcare and Electronics.

Portal Biotechnologies Announces $5M Pre-Seed Round Led By Pear VC

Retrieved on: 
Tuesday, March 19, 2024
Other Manufacturing, Other Science, Technology, Research, General Health, Engineering, Manufacturing, Pharmaceutical, Other Professional Services, Medical Devices, Health Technology, Finance, Genetics, Nanotechnology, Professional Services, Artificial Intelligence, Biotechnology, Other Technology, Health, Hardware, Science, Innovation Center station, Gene editing, Cell, BRIC, RNA, Pear VC, Conscience, Capital, Messenger, Hope, Genome, Doctor of Philosophy, Bayer, Antibody, Kendall Square, CRISPR, Drug development, Multimedia, Small RNA, Silicon, Fine chemical

Today, Portal Biotechnologies, Inc. (“Portal”), a cell engineering platform company, announced a $5M pre-seed round led by Pear VC, with participation from Conscience VC and 10x Capital.

Key Points: 
  • Today, Portal Biotechnologies, Inc. (“Portal”), a cell engineering platform company, announced a $5M pre-seed round led by Pear VC, with participation from Conscience VC and 10x Capital.
  • Portal is committed to ensuring broad accessibility of its platform to enable a variety of research and therapeutic applications.
  • The company was founded by Armon Sharei, Ph.D., founder and former CEO of SQZ Biotechnologies.
  • “We are very excited to join the Portal team and support their mission to solve one of the field's major long-standing challenges,” said Eddie Eltoukhy, Partner and lead investor from Pear VC.

SCHOTT Pharma to Expand in the U.S. with New Prefillable Syringe Manufacturing Facility in Wilson, North Carolina

Retrieved on: 
Monday, March 18, 2024
General Health, Manufacturing, Health, Pharmaceutical, Packaging, Museum, Obesity, Organization, University, Diabetes, Patient, City, Transport, Messenger, Glass, Commerce, Syringe, Wilson Community College, Research Triangle, SCHOTT, Injection, North Carolina State University, Multimedia, Vaccine, Economic development

SCHOTT Pharma plans to make Wilson, North Carolina home to its newest site.

Key Points: 
  • SCHOTT Pharma plans to make Wilson, North Carolina home to its newest site.
  • View the full release here: https://www.businesswire.com/news/home/20240318311726/en/
    Many of the US-based pharmaceutical companies use SCHOTT syriQ® prefillable glass syringes as a leading choice for vaccines, biologics, and GLP-1 medications.
  • On average, more than 25,000 injections per minute are provided to patients worldwide through a product produced by SCHOTT Pharma.
  • SCHOTT Pharma partnered with several organizations throughout the project, including the North Carolina Department of Commerce and the Economic Development Partnership of North Carolina, the North Carolina General Assembly, the North Carolina Community College System, Commerce’s Division of Workforce Solutions, Wilson County, the City of Wilson, the Wilson Economic Development Council, the North Carolina Biotechnology Center, and the Biomanufacturing Training and Education Center at North Carolina State University.

COVID-19 Monthly Newsletter Service - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Publishing, Health, FDA, COVID-19, Communications, Clinical Trials, MHLW, CSL, Abivax, AstraZeneca, Partnership, University, Ageing, EUL, Arcturus Therapeutics, UNICEF, Bharat Biotech, Ministry of Health, XBB, Messenger, Laboratory, World Health Organization, OTC, Therapy, Johnson & Johnson, Vaccination, Rapid antigen test, Phase II, WHO, CSL Limited, Ministry, Vaccine, Marketing, Fulcrum, UN, Pharmaceutical industry

The "COVID-19 Monthly Snapshot" newsletter has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "COVID-19 Monthly Snapshot" newsletter has been added to ResearchAndMarkets.com's offering.
  • In November 2023, 64 investigational drugs were active in Phase 3 of clinical development.
  • Globally, the overall confirmed cases of COVID-19 reached more than 772 million as of November 22, 2023.
  • Fifty-eight COVID-19 vaccines were evaluated in Phase 3, 40 in Phase 2, 84 in Phase 1, and 199 in pre-clinical stages.

Ricoh and ERS Genomics Enter into CRISPR/Cas9 License Agreement

Retrieved on: 
Wednesday, March 13, 2024
Health, Medical Devices, Health Technology, Genetics, Research, Science, Biotechnology, Chiyoda, Tokyo, Ricoh, B cell, Gene editing, Cell, Drug discovery, Intelligence, Acceleration, Patient, RNA, DNA, Acquisition, Messenger, Sumitomo Corporation, IPS, Regenerative medicine, Multinational corporation, Genomics, CRISPR, Drug development, Cas9, Vaccine

Ricoh Company, Ltd. today announced a non-exclusive licensing agreement in the USA and Japan with ERS Genomics Limited ("ERS Genomics") for access to the foundational CRISPR/Cas9 genome editing technology patents managed by ERS Genomics.

Key Points: 
  • Ricoh Company, Ltd. today announced a non-exclusive licensing agreement in the USA and Japan with ERS Genomics Limited ("ERS Genomics") for access to the foundational CRISPR/Cas9 genome editing technology patents managed by ERS Genomics.
  • In 2022, Ricoh completed the acquisition of Elixirgen Scientific, Inc. (Baltimore, Maryland, USA).
  • Ricoh continues to contribute to the acceleration of drug development research through the diverse solutions provided by Elixirgen Scientific.
  • Summit Pharmaceuticals International Corporation (Chiyoda-ku, Tokyo, Japan), a subsidiary of Sumitomo Corporation (Chiyoda-ku, Tokyo, Japan), is the exclusive representative of ERS Genomics in Japan.